Shots:

• The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources- financial contribution- and experience from both the company
• The alliance strengthens n-Lorem’s mission to bring immediate hope and rapid treatment to ultra-rare disease patients in need
• n-Lorem Foundation provides a free and lifetime supply of ASO medicines to patients who have diseases caused by extremely rare mutations (1 to 30 patients) globally

  Ref: BusinessWire | Image: PRNewswire